KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure. PMID 36151557 · Cardiovasc Diabetol · 2022-Sep-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study. PMID 36138362 · BMC Pulm Med · 2022-Sep-22 The record describes a retrospective, population-based, real-world study with no evidence of being a Phase III/IIIb or Phase II/III randomized controlled trial with a drug intervention. The authors explicitly call for future randomized studies, confirming the lack of randomization in this report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. PMID 35737911 · Blood · 2022-Sep-22 The record describes a Phase III randomized trial with a drug intervention and a time-to-event endpoint, but the abstract focuses on the predictive performance of MRD biomarkers and kinetics, not the primary efficacy comparison of the drug intervention (lenalidomide maintenance vs observation). Therefore, it does not qualify as an original formal-result report of a primary/key secondary efficacy endpoint for the drug intervention as required by the adjudication criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) score and diabetes risk in the Diabetes Prevention Program Outcomes Study (DPPOS). PMID 36131333 · BMC Nutr · 2022-Sep-21 The record describes a study on diabetes prevention in a high-risk population using a lifestyle score derived from cancer prevention recommendations. While the underlying trial (DPP/DPPOS) was randomized, the analysis presented is not an oncology trial, does not have a drug-containing intervention as the focus (the metformin arm is a comparator, but the study examines a lifestyle score), and the primary endpoint is diabetes risk, not a cancer-related time-to-event outcome. Therefore, it does not meet the eligibility criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial. PMID 36130755 · BMJ Open · 2022-Sep-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study). PMID 36525606 · Chin Med J (Engl) · 2022-Sep-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Synbiotics, prebiotics and probiotics for solid organ transplant recipients. PMID 36126902 · Cochrane Database Syst Rev · 2022-Sep-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. PMID 35666982 · J Clin Oncol · 2022-Sep-20 The record describes a prognostic biomarker analysis (CTC-high) conducted within the FORTE randomized trial. While it analyzes time-to-event endpoints (PFS, OS) in a human oncology context, it is not a report of the trial's primary drug intervention efficacy results. It is a secondary/biomarker-focused analysis, and the specific drug interventions are not defined or evaluated in this report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). PMID 35476508 · J Clin Oncol · 2022-Sep-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer. PMID 36123093 · BMJ Open · 2022-Sep-19 This is a phase III clinical trial protocol for a diagnostic imaging study (PSMA PET/CT vs. mpMRI) in prostate cancer. It is a non-randomized, single-arm, paired comparison design without a drug intervention. The primary outcome is diagnostic accuracy (sensitivity, specificity), not a time-to-event efficacy endpoint like OS or PFS. The publication is explicitly a protocol without reported results.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. PMID 36117201 · NPJ Breast Cancer · 2022-Sep-19 The study is an eligible phase III randomized drug trial in oncology, but the abstract does not establish the presence of a primary/key secondary time-to-event endpoint (KM/HR). It reports an event count for invasive disease-free survival (IDFS) in a subgroup, but without formal time-to-event analysis metrics. Therefore, it does not meet the strict inclusion criterion for time-to-event efficacy.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Management of elderly patients with unresectable pancreatic cancer. PMID 35789391 · Jpn J Clin Oncol · 2022-Sep-18 The record is a review article discussing treatment of elderly patients with pancreatic cancer, referencing phase III trials but not presenting original results from a specific trial. It does not contain a Kaplan-Meier plot, hazard ratio, or any primary time-to-event efficacy endpoint data from a randomized trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. PMID 36116480 · Lancet · 2022-Sep-17 The study is a randomized, placebo-controlled Phase 3 trial of a drug (linzagolix) for symptomatic uterine fibroids, which is a non-malignant condition. The primary endpoint is a binary response rate (reduction in heavy menstrual bleeding), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or an analysis using Kaplan-Meier or reporting a hazard ratio. Therefore, it does not meet the oncology or time-to-event criteria for inclusion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer - results of a randomized phase III trial (RAREST-02). PMID 36115962 · BMC Cancer · 2022-Sep-17 The study is a randomized Phase III trial in oncology with human subjects and reports primary results. However, it is excluded because the intervention (mobile app) is not a drug-containing intervention, and the primary and secondary endpoints are acute toxicity rates (toxicity grade proportions), not time-to-event efficacy endpoints such as OS, PFS, DFS, or TTP, which are required for this adjudication.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of high-quality nursing care on quality of life, survival, and recurrence in patients with advanced nonsmall cell lung cancer. PMID 36123938 · Medicine (Baltimore) · 2022-Sep-16 The study is a randomized controlled trial in advanced NSCLC with survival/recurrence endpoints, but it evaluates a nursing intervention, not a drug-containing intervention. Therefore, it fails the drug intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic nomograms for predicting overall survival and cancer-specific survival of patients with very early-onset colorectal cancer: A population‑based analysis. PMID 35348447 · Bosn J Basic Med Sci · 2022-Sep-16 The record describes a population-based, prognostic nomogram development and validation study for very early-onset colorectal cancer using SEER data. Although tagged as a 'Randomized Controlled Trial' in metadata, the study is a retrospective analysis with random assignment only for internal model validation (training/validation cohorts), not a randomized clinical trial of a therapeutic intervention. It lacks any drug intervention, which is a required criterion. Phase evidence is also unclear.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial. PMID 36139636 · Cancers (Basel) · 2022-Sep-15 The study is a randomized, phase III trial in oncology (prostate cancer), but the intervention is a medical device (Hemopatch), not a drug, and the primary efficacy endpoint is drain output volume, which is not a time-to-event endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study. PMID 36107485 · Elife · 2022-Sep-15 The study includes a human clinical cohort and a preclinical randomized component. However, the human clinical part is a retrospective analysis of patients receiving neoadjuvant chemotherapy, not a report of a Phase III, IIIb, or Phase II/III randomized controlled trial. The preclinical component involves randomized animal experiments but does not meet the criteria for a human trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Short-term Outcomes of Laparoscopy-Assisted vs Open Surgery for Patients With Low Rectal Cancer: The LASRE Randomized Clinical Trial. PMID 36107416 · JAMA Oncol · 2022-Sep-15 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effect of Total Intravenous Anesthesia on Postoperative Pulmonary Complications in Patients Undergoing Microvascular Reconstruction for Head and Neck Cancer: A Randomized Clinical Trial. PMID 36107412 · JAMA Otolaryngol Head Neck Surg · 2022-Sep-15 The study is an oncology-related randomized trial in human patients, but it is not eligible because it does not meet the criteria for a definitive (Phase III/IIIb or Phase II/III) drug trial with a primary time-to-event efficacy endpoint. The intervention compares anesthetic techniques (propofol-based TIVA vs. inhalational anesthesia), which is not a therapeutic drug intervention in the oncology sense (e.g., chemotherapy, targeted therapy). The primary outcome is postoperative pulmonary complications, not a survival or progression-free time-to-event endpoint like OS, PFS, DFS, etc., and no Kaplan-Meier or HR is reported for such an endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endobiliary Ablation Combined with Immune Nutrition Improves Quality of Life: A Preliminary Clinical Study in Patients with Advanced Malignant Obstructive Jaundice. PMID 36104943 · Med Sci Monit · 2022-Sep-15 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer. PMID 35920686 · Clin Cancer Res · 2022-Sep-15 This is a biomarker-only subgroup analysis (ESR1 amplification) of the tamoxifen-only arm of the ABCSG-06 trial. It is not a primary or key secondary efficacy report of the randomized trial comparing drug interventions. The phase is not definitively established as Phase III/IIIb or Phase II/III from the provided metadata, though the trial ABCSG-06 is likely Phase III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Assessing fetal human neural stem cells tumorigenicity potential in athymic rats with penetrating traumatic brain injury (pTBI). PMID 35810769 · Brain Res · 2022-Sep-15 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. PMID 35802667 · Clin Cancer Res · 2022-Sep-15 The study is a secondary, biomarker-focused analysis of a randomized trial. While it reports a PFS hazard ratio for a transcriptomic subgroup, it does not represent the primary or key secondary efficacy results of the main trial. The trial phase is not explicitly confirmed in the metadata as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial. PMID 35802649 · Clin Cancer Res · 2022-Sep-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention. PMID 35797441 · Cancer · 2022-Sep-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review. PMID 36104789 · Radiat Oncol · 2022-Sep-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The CHARTER-Ireland trial: can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratory support in Ireland: a study protocol and statistical analysis plan for a randomised control trial. PMID 36104785 · Trials · 2022-Sep-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma. PMID 36104135 · BMJ Open · 2022-Sep-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Novel postoperative nomograms for predicting individual prognoses of hepatitis B-related hepatocellular carcinoma with cirrhosis. PMID 36100893 · BMC Surg · 2022-Sep-13 Study is an oncology prognostic model development paper with time-to-event endpoints, but it is not a Phase III or Phase II/III randomized trial of a drug intervention. The randomized aspect refers only to the split of patients into training/validation cohorts for model development, not to a clinical trial comparing therapeutic arms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial. PMID 36100263 · BMJ · 2022-Sep-13 The record describes a randomized, controlled trial of tinzaparin for perioperative thromboprophylaxis in colorectal cancer patients, reporting disease-free survival and overall survival with hazard ratios. However, the trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata. The deterministic review signal 'phase3_evidence_unclear' correctly identifies this missing required criterion. While the trial is likely a definitive efficacy trial, the instructions prohibit inferring missing phase evidence. Therefore, the criterion 'phase3_or_definitive' cannot be set to true, making the record ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Effect on ankylosing spondylitis at early-middle stage and bone marrow edema of sacroiliac joint treated with acupuncture and governor vessel moxibustion]. PMID 36075591 · Zhongguo Zhen Jiu · 2022-Sep-12 The study is a randomized controlled trial with a drug intervention (recombinant human tumor necrosis factor receptor-antibody) but evaluates ankylosing spondylitis (non-oncology), uses clinical symptom/disease activity scores (SPARCC, BASDAI, etc.) as endpoints, and does not report a time-to-event efficacy endpoint. Phase is not specified.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical Benefit Scales and Trial Design: Some Statistical Issues. PMID 35583264 · J Natl Cancer Inst · 2022-Sep-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study. PMID 36076163 · BMC Geriatr · 2022-Sep-08 The record is an original prognostic nomogram study for cancer-specific survival in a non-randomized, retrospective cohort. It is not a randomized trial, lacks a drug intervention as the primary focus, and does not report comparative efficacy results from a Phase II/III trial. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition. PMID 36068332 · NPJ Precis Oncol · 2022-Sep-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial. PMID 36068213 · Blood Cancer J · 2022-Sep-06 The study is an oncology randomized controlled trial with drug intervention and time-to-event endpoints (EFS, OS), and it reports original results. However, the specific trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata or abstract. The deterministic review flagged phase evidence as unclear, and without explicit phase information, the 'phase3_or_definitive' criterion cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation. PMID 35444013 · Int J Gynecol Cancer · 2022-Sep-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Accumulation of copy number alterations and clinical progression across advanced prostate cancer. PMID 36059000 · Genome Med · 2022-Sep-05 The abstract describes a genomic biomarker analysis (copy number alterations) performed within the control arm of a randomized trial (STAMPEDE). It does not explicitly report a time-to-event efficacy endpoint (e.g., OS, PFS) for a drug-containing intervention arm compared to control, nor does it specify the trial phase or provide Kaplan-Meier curves/HR for a primary/secondary efficacy endpoint. The study is a biomarker-focused secondary analysis, not a report of the trial's primary drug efficacy results.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Analgesic efficacy of the superficial versus deep serratus plane blocks for mastectomy with axillary clearance: A randomized controlled trial. PMID 36107598 · Medicine (Baltimore) · 2022-Sep-02 The study is a randomized trial in breast cancer patients, but it is not an oncology efficacy trial. It is an analgesic efficacy study for surgical pain management, with no anti-cancer drug intervention and no time-to-event endpoints (e.g., OS, PFS). It does not meet the criteria for a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study. PMID 36056419 · Trials · 2022-Sep-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Opening the Conversation: study protocol for a Phase III trial to evaluate a couple-based intervention to reduce reproductive and sexual distress among young adult breast and gynecologic cancer survivor couples. PMID 36056413 · Trials · 2022-Sep-02 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. PMID 36056374 · Breast Cancer Res · 2022-Sep-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Perioperative oral nutritional support for patients diagnosed with primary colon adenocarcinoma undergoing radical surgical procedures -Peri-Nutri Trial: study protocol for a randomized controlled trial. PMID 36050804 · BMC Nutr · 2022-Sep-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial. PMID 36050712 · BMC Med · 2022-Sep-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Nomograms for predicting overall and cancer-specific survival of patients with chromophobe renal cell carcinoma after nephrectomy: a retrospective SEER-based study. PMID 36581979 · BMJ Open · 2022-Sep-01 The record is a retrospective cohort study developing prognostic nomograms for chromophobe renal cell carcinoma after nephrectomy. It is oncological and human, reports OS and CSS (time-to-event endpoints), and presents original results. However, it is not a randomized trial (retrospective, uses patient division for model building/validation), does not establish a Phase III or Phase II/III trial phase, and has no drug-containing intervention (nephrectomy is a surgical treatment). Therefore, it does not meet the eligibility criteria for a Phase III/IIIb or Phase II/III randomized drug trial with a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial. PMID 36169959 · JAMA Netw Open · 2022-Sep-01 The trial is for multiple sclerosis, which is not a human malignant neoplasm. While it meets criteria for randomized, drug intervention, and time-to-event endpoint, the primary oncology requirement is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ELEVATE - evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial. PMID 36050653 · BMC Cancer · 2022-Sep-01 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of Background Music in the Operating Room on Surgical Outcomes: A Prospective Single-Blinded Case-Control Study. PMID 35972164 · J Am Coll Surg · 2022-Sep-01 The record describes a randomized controlled trial in oncology patients (breast cancer), but it does not meet key eligibility criteria: the phase is not Phase III/IIIb or Phase II/III (it is a single-center prospective study), the intervention is not a drug (it is background music), and the primary efficacy endpoint is operating time (not a time-to-event endpoint). Recurrence rates are reported as percentages without time-to-event analysis (no Kaplan-Meier, HR, or mention of OS/PFS/DFS/EFS/RFS/TTP).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. PMID 35921122 · JAMA Surg · 2022-Sep-01 The report is a randomized, Phase III (implied by 'Multicenter Selective Lymphadenectomy Trial') clinical trial in oncology (melanoma) with a time-to-event primary endpoint (in-basin nodal recurrence). However, it evaluates a surgical intervention (sentinel lymph node biopsy vs. completion lymph node dissection), not a drug-containing intervention. Therefore, it does not meet the criterion for a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. PMID 35857290 · JAMA Dermatol · 2022-Sep-01 The study is an oncology Phase 3 randomized trial with a drug-containing intervention (topical hypericin) and original results. However, the primary endpoint is a categorical response rate (index lesion response rate), not a time-to-event endpoint. The intervention is a topical photodynamic therapy, which may be considered a device or procedure rather than a systemic drug administration per the criteria. No time-to-event outcomes (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analyses are reported in the abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -